EE04703B1 - Migreeni kordumise ärahoimine - Google Patents

Migreeni kordumise ärahoimine

Info

Publication number
EE04703B1
EE04703B1 EEP200100061A EEP200100061A EE04703B1 EE 04703 B1 EE04703 B1 EE 04703B1 EE P200100061 A EEP200100061 A EE P200100061A EE P200100061 A EEP200100061 A EE P200100061A EE 04703 B1 EE04703 B1 EE 04703B1
Authority
EE
Estonia
Prior art keywords
migraine
recurrence
prevention
Prior art date
Application number
EEP200100061A
Other languages
English (en)
Estonian (et)
Inventor
Colin Jackson Neville
Uden Stephen
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of EE200100061A publication Critical patent/EE200100061A/xx
Publication of EE04703B1 publication Critical patent/EE04703B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/4045Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200100061A 1998-07-30 1999-06-14 Migreeni kordumise ärahoimine EE04703B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9816556.6A GB9816556D0 (en) 1998-07-30 1998-07-30 Therapy
PCT/IB1999/001105 WO2000006161A1 (en) 1998-07-30 1999-06-14 Prevention of migraine recurrence

Publications (2)

Publication Number Publication Date
EE200100061A EE200100061A (et) 2002-06-17
EE04703B1 true EE04703B1 (et) 2006-10-16

Family

ID=10836395

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100061A EE04703B1 (et) 1998-07-30 1999-06-14 Migreeni kordumise ärahoimine

Country Status (35)

Country Link
EP (3) EP1100499B1 (is)
JP (1) JP3824863B2 (is)
KR (2) KR20030078876A (is)
CN (2) CN1522697A (is)
AP (1) AP1402A (is)
AT (1) ATE261304T1 (is)
AU (1) AU3952199A (is)
BG (1) BG65309B1 (is)
BR (1) BR9912588A (is)
CA (1) CA2338901C (is)
CZ (1) CZ2001357A3 (is)
DE (1) DE69915486T2 (is)
DK (1) DK1100499T3 (is)
EA (2) EA004036B1 (is)
EE (1) EE04703B1 (is)
ES (1) ES2214027T3 (is)
GB (1) GB9816556D0 (is)
GE (2) GEP20043157B (is)
HR (1) HRP20010079A2 (is)
HU (1) HUP0103424A3 (is)
ID (1) ID26996A (is)
IL (1) IL140169A0 (is)
IS (1) IS2253B (is)
NO (1) NO20010489L (is)
NZ (2) NZ508736A (is)
OA (1) OA11576A (is)
PL (1) PL194611B1 (is)
PT (1) PT1100499E (is)
SG (1) SG125910A1 (is)
SK (1) SK1182001A3 (is)
TR (1) TR200100314T2 (is)
TW (2) TW537893B (is)
UA (1) UA76399C2 (is)
WO (1) WO2000006161A1 (is)
YU (2) YU6401A (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8022095B2 (en) 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
PT1575566E (pt) * 2002-12-26 2012-03-29 Pozen Inc Formas de dosagem em multicamada contendo naproxeno e triptanos
WO2004089365A1 (en) 2003-04-11 2004-10-21 Pfizer Limited Pharmaceutical combination comprising eletriptan and sodium bicarbonate
GB2407498B (en) * 2003-10-30 2008-06-11 Cipla Ltd Oral formulations for 5-HT receptor agonists with reduced degradation of active ingredient
FR2926721B1 (fr) * 2008-01-30 2011-07-22 Philippe Perovitch Forme galenique pour l'adminsitration par voie trans-muqueuse de triptans
CN102088966B (zh) 2008-06-20 2015-06-10 阿尔法制药有限公司 药物制剂
EP2490669B1 (en) * 2009-10-23 2017-01-11 Fortuderm Ltd. Triptans for the treatment of psoriasis
HUE037732T2 (hu) * 2012-04-18 2018-09-28 Contera Pharma Aps A mozgászavarok fejlett kezelésére alkalmas, szájon át szedhetõ gyógyszerészeti készítmény
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法
CN104523709A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种含有琥珀酸夫罗曲坦的复方缓释制剂
KR102443161B1 (ko) 2016-07-11 2022-09-14 콘테라 파르마 에이/에스 아침 운동 불능을 치료하기 위한 박동성 약물 전달 시스템

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE157361T1 (de) * 1990-10-15 1997-09-15 Pfizer Indolderivate
EP0546593B1 (en) * 1991-10-30 1997-09-03 Glaxo Group Limited Multi-layered compositions containing histamine or serotonin antagonists
US5464633A (en) * 1994-05-24 1995-11-07 Jagotec Ag Pharmaceutical tablets releasing the active substance after a definite period of time
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
US5744482A (en) * 1994-10-05 1998-04-28 Eli Lilly And Company Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
EP1024833A1 (en) * 1996-07-11 2000-08-09 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
EP0999841B1 (en) * 1997-07-03 2001-10-17 Pfizer Limited Pharmaceutical compositions containing eletriptan hemisulphate and caffeine
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape

Also Published As

Publication number Publication date
DE69915486D1 (de) 2004-04-15
EP1100499B1 (en) 2004-03-10
HK1038198A1 (en) 2002-03-08
BG65309B1 (bg) 2008-01-31
CZ2001357A3 (cs) 2001-10-17
EP1466601A3 (en) 2005-04-13
NZ508736A (en) 2003-09-26
SG125910A1 (en) 2006-10-30
TWI248362B (en) 2006-02-01
ID26996A (id) 2001-02-22
CA2338901C (en) 2008-02-19
CN1309560A (zh) 2001-08-22
GEP20043157B (en) 2004-01-26
WO2000006161A1 (en) 2000-02-10
PT1100499E (pt) 2004-06-30
IL140169A0 (en) 2002-02-10
NZ527625A (en) 2005-01-28
TR200100314T2 (tr) 2001-06-21
KR100441732B1 (ko) 2004-07-27
TW537893B (en) 2003-06-21
NO20010489D0 (no) 2001-01-29
OA11576A (en) 2004-07-01
PL345803A1 (en) 2002-01-02
TW200300674A (en) 2003-06-16
HRP20010079A2 (en) 2002-02-28
JP3824863B2 (ja) 2006-09-20
AP2001002056A0 (en) 2001-03-31
ATE261304T1 (de) 2004-03-15
KR20030078876A (ko) 2003-10-08
HUP0103424A3 (en) 2003-05-28
BR9912588A (pt) 2001-05-02
EA200100089A1 (ru) 2001-08-27
DK1100499T3 (da) 2004-06-14
JP2002521446A (ja) 2002-07-16
SK1182001A3 (en) 2001-10-08
GEP20063719B (en) 2006-01-10
EP1466601A2 (en) 2004-10-13
AP1402A (en) 2005-04-29
KR20010079582A (ko) 2001-08-22
GB9816556D0 (en) 1998-09-30
UA76399C2 (en) 2006-08-15
NO20010489L (no) 2001-03-26
CN1522697A (zh) 2004-08-25
IS2253B (is) 2007-06-15
EA004036B1 (ru) 2003-12-25
ES2214027T3 (es) 2004-09-01
EA200201149A1 (ru) 2003-02-27
CN1155379C (zh) 2004-06-30
EE200100061A (et) 2002-06-17
YU20303A (sh) 2006-08-17
AU3952199A (en) 2000-02-21
EP1100499A1 (en) 2001-05-23
HUP0103424A2 (hu) 2002-02-28
PL194611B1 (pl) 2007-06-29
CA2338901A1 (en) 2000-02-10
DE69915486T2 (de) 2005-03-03
IS5771A (is) 2000-12-15
BG105277A (en) 2001-11-30
YU6401A (sh) 2004-03-12
EP1435237A1 (en) 2004-07-07

Similar Documents

Publication Publication Date Title
IS5574A (is) Útskiptir Xa-þáttar oxóasaheterósýklýl-tálmar
NO20005928D0 (no) Bicykliske pyrimidiner og bicykliske 3,4-dihydropyrimidiner som inhibitorer av cellulær proliferasjon
NO20021596L (no) Brannslukningsinstallasjon
PT927183E (pt) Inibidores espirociclicos de metaloproteases
EE200100061A (et) Migreeni kordumise ärahoimine
PT1022396E (pt) Combinacao de duche
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
NO20006262D0 (no) Fôring av rör
MA24877A1 (fr) INHIBITEURS DE PROTéASES
ATA146797A (de) Schallschutzwand
DE69818311D1 (de) Festkörperüberstromrelais
DE59912020D1 (de) Duschgel
PT1232141E (pt) Eteres de o-desmetil-venlafaxina
HU0400568D0 (en) Prevention of migraine recurrence
HU0400567D0 (en) Prevention of migraine recurrence
AU2003213493B2 (en) Prevention of migraine recurrence
DE69931153D1 (de) Steigrohrsicherung
IT1304635B1 (it) Mezzi di raccordo
NO980820L (no) Dusjhode
SI1100499T1 (en) Use of eletriptan for the prevention of migraine recurrence
SE9801284D0 (sv) Installation av spishäll
FI3524U1 (fi) Yhdistelmäkoura
DE59906917D1 (de) Duschabtrennung
EE03357B1 (et) Tuletõrjehüdrant

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

MM4A Lapsed by not paying the annual fees

Effective date: 20090614